Contravisory Investment Management Inc. Takes $1.22 Million Position in Charles River Laboratories International, Inc. $CRL

Contravisory Investment Management Inc. bought a new position in Charles River Laboratories International, Inc. (NYSE:CRL) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 6,129 shares of the medical research company’s stock, valued at approximately $1,223,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of CRL. Vanguard Group Inc. increased its holdings in Charles River Laboratories International by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 5,839,743 shares of the medical research company’s stock valued at $913,686,000 after acquiring an additional 27,989 shares during the last quarter. Ariel Investments LLC grew its position in shares of Charles River Laboratories International by 28.6% during the second quarter. Ariel Investments LLC now owns 1,415,348 shares of the medical research company’s stock valued at $214,751,000 after purchasing an additional 314,572 shares in the last quarter. Invesco Ltd. grew its position in shares of Charles River Laboratories International by 1.0% during the third quarter. Invesco Ltd. now owns 1,249,178 shares of the medical research company’s stock valued at $195,446,000 after purchasing an additional 12,035 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of Charles River Laboratories International by 13.4% in the third quarter. Bank of America Corp DE now owns 1,163,348 shares of the medical research company’s stock worth $182,017,000 after purchasing an additional 137,335 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Charles River Laboratories International by 11.9% in the third quarter. Dimensional Fund Advisors LP now owns 1,130,905 shares of the medical research company’s stock worth $176,909,000 after purchasing an additional 120,207 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Up 2.6%

Shares of NYSE CRL opened at $157.59 on Tuesday. The business’s 50 day moving average is $184.19 and its two-hundred day moving average is $180.79. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.29 and a quick ratio of 1.02. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $228.88. The stock has a market capitalization of $7.76 billion, a P/E ratio of -53.24, a PEG ratio of 2.63 and a beta of 1.64.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 18th. The medical research company reported $2.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.33 by $0.06. The business had revenue of $994.23 million during the quarter, compared to analyst estimates of $986.98 million. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The company’s revenue for the quarter was down .8% on a year-over-year basis. During the same period last year, the company earned $2.66 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. As a group, research analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on CRL. Evercore increased their price target on Charles River Laboratories International from $250.00 to $260.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Wall Street Zen downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st. Bank of America upgraded Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 target price for the company in a research report on Monday, December 15th. Citigroup raised their target price on shares of Charles River Laboratories International from $200.00 to $265.00 and gave the company a “buy” rating in a report on Friday, January 16th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Charles River Laboratories International from $165.00 to $190.00 and gave the stock a “neutral” rating in a research report on Monday, December 15th. Ten equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $206.15.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.